GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia

GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia

Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ruxolitinib Nearly all myelofibrosis patients globally are estimated to develop anaemia over the course of the disease, and...

menu
menu